An Open-Label, One-Arm Phase II Extension Study to Evaluate Safety and Tolerability of MIV-711 in Patients with Knee Joint Osteoarthritis

Trial Profile

An Open-Label, One-Arm Phase II Extension Study to Evaluate Safety and Tolerability of MIV-711 in Patients with Knee Joint Osteoarthritis

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 14 Sep 2017

At a glance

  • Drugs MIV 711 (Primary)
  • Indications Osteoarthritis
  • Focus Adverse reactions
  • Sponsors Medivir AB
  • Most Recent Events

    • 14 Sep 2017 According to a Medivir AB media release, the independent Data Monitoring Committee (DMC) has again recommended continuation of the extension study without modifications, based on the planned final review of the accumulated safety data.
    • 24 Aug 2017 Planned End Date changed from 1 Feb 2018 to 1 Dec 2017.
    • 25 Jul 2017 According to a Medivir AB media release, data from this study will be available in the first quarter of 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top